03-20-2019 | Peripheral arterial disease | News
Patients with type 2 diabetes and peripheral artery disease may derive greater absolute benefit from dapagliflozin than those without the comorbidity due to their increased risk for cardiovascular and renal events, DECLARE-TIMI 58 data show.
11-14-2018 | Cardiovascular outcomes | Editorial | Article
Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.
06-25-2018 | Cardiovascular disorders | Review | Article
Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5
09-28-2017 | Physical activity | Book chapter | Article
Mays RJ, Whipple MO, Treat-Jacobson D. In: Diabetes and Exercise. Edited by J Reusch et al. Humana Press, Cham, 2017. doi: 10.1007/978-3-319-61013-9_22
06-01-2017 | Diabetic foot | Review | Article
Salvo NL, Walsh MD, Brewster LP. Curr Treat Options Cardio Med 2017; 19: 55. doi: 10.1007/s11936-017-0547-1